CPA
TBPH icon

Capital Performance Advisors’s Theravance Biopharma TBPH Stock Holding History

Capital Performance Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$40 – 2405
2024
Q3 		$40 Buy
+5
New +$43 ﹤0.01% 2811

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Capital Performance Advisors's TBPH Position: Q4 2024 in Review

Capital Performance Advisors sold out of Theravance Biopharma (TBPH) in Q4 2024, closing a stake of 5 shares — an estimated $40 sold.

Capital Performance Advisors first reported a position in TBPH in Q3 2024 and held it in 1 quarter. The position peaked at $40 in Q3 2024. 128 funds tracked by Wall St. Rank hold TBPH as of Q4 2024.

  • Capital Performance Advisors reported no remaining Theravance Biopharma position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 5 Theravance Biopharma shares in Q4 2024, an estimated $40.
  • Capital Performance Advisors first reported a position in Theravance Biopharma in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Theravance Biopharma position peaked at $40 in Q3 2024.
  • 128 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.